Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00987753 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Safety and Tolerability of L-377202
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00987753 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants.
The verdict
NCT00987753, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of L-377202 including the dose-limiting adverse effects of treatment with L-377202, and (3) assess the pharmacokinetics of various doses of L-377202 and the plasma profile of liberated doxorubicin and leu-doxorubicin.
Interventions
- DRUG L-377202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 1999-03 |
| Est. Completion | 2001-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00987753
The ClinicalTrials.gov registry entry for NCT00987753 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-377202 is the first listed.
NCT00987753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00987753 about?
NCT00987753 is a clinical study titled "Study Evaluating the Safety and Tolerability of L-377202". The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of L-377202 including the dose-limiting adverse effects of treatment with L-377202, and (3) assess the pharmacokinetics of va...
What is the current status of trial NCT00987753?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 1999-03. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00987753?
The interventions under investigation include: L-377202 (DRUG).
Who is sponsoring clinical trial NCT00987753?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.